Search

Your search keyword '"LANDEWÉ, ROBERT B. M."' showing total 544 results
Start Over Author "LANDEWÉ, ROBERT B. M."
544 results on '"LANDEWÉ, ROBERT B. M."'

6. ASAS consensus definition of early axial spondyloarthritis.

Author

Navarro-Compán, Victoria, Benavent, Diego, Capelusnik, Dafne, van der Heijde, Désirée, Landewé, Robert B. M., Poddubnyy, Denis, van Tubergen, Astrid, Baraliakos, Xenofon, Van den Bosch, Filip E., van Gaalen, Floris A., Gensler, Lianne, López-Medina, Clementina, Marzo-Ortega, Helena, Molto, Anna, Pérez-Alamino, Rodolfo, Rudwaleit, Martin, van de Sande, Marleen, Sengupta, Raj, Weber, Ulrich, and Ramiro, Sofia

Published
2024
Full Text
View/download PDF

8. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature

Author

van der Heijde, Désirée, primary, Molto, Anna, additional, Ramiro, Sofia, additional, Braun, Jürgen, additional, Dougados, Maxime, additional, van Gaalen, Floris A, additional, Gensler, Lianne S, additional, Inman, Robert D, additional, Landewé, Robert B M, additional, Marzo-Ortega, Helena, additional, Navarro-Compán, Victoria, additional, Phoka, Andri, additional, Poddubnyy, Denis, additional, Protopopov, Mikhail, additional, Reveille, John, additional, Rudwaleit, Martin, additional, Sampaio-Barros, Percival, additional, Sepriano, Alexandre, additional, Sieper, Joachim, additional, Van den Bosch, Filip E, additional, van der Horst-Bruinsma, Irene, additional, Machado, Pedro M, additional, and Baraliakos, Xenofon, additional

Published
2023
Full Text
View/download PDF

10. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Author

Ramiro, Sofia, Nikiphorou, Elena, Sepriano, Alexandre, Ortolan, Augusta, Webers, Casper, Baraliakos, Xenofon, Landewé, Robert B M, Van den Bosch, Filip E, Boteva, Boryana, Bremander, Ann, Carron, Philippe, Ciurea, Adrian, van Gaalen, Floris A, Géher, Pál, Gensler, Lianne, Hermann, Josef, de Hooge, Manouk, Husakova, Marketa, Kiltz, Uta, López-Medina, Clementina, Machado, Pedro M, Marzo-Ortega, Helena, Molto, Anna, Navarro-Compán, Victoria, Nissen, Michael J, Pimentel-Santos, Fernando M, Poddubnyy, Denis, Proft, Fabian, Rudwaleit, Martin, Telkman, Mark, Zhao, Sizheng Steven, Ziade, Nelly, van der Heijde, Désirée, Ramiro, Sofia, Nikiphorou, Elena, Sepriano, Alexandre, Ortolan, Augusta, Webers, Casper, Baraliakos, Xenofon, Landewé, Robert B M, Van den Bosch, Filip E, Boteva, Boryana, Bremander, Ann, Carron, Philippe, Ciurea, Adrian, van Gaalen, Floris A, Géher, Pál, Gensler, Lianne, Hermann, Josef, de Hooge, Manouk, Husakova, Marketa, Kiltz, Uta, López-Medina, Clementina, Machado, Pedro M, Marzo-Ortega, Helena, Molto, Anna, Navarro-Compán, Victoria, Nissen, Michael J, Pimentel-Santos, Fernando M, Poddubnyy, Denis, Proft, Fabian, Rudwaleit, Martin, Telkman, Mark, Zhao, Sizheng Steven, Ziade, Nelly, and van der Heijde, Désirée

Abstract

OBJECTIVES: To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA).METHODS: Following the EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment of axSpA. In a task force meeting, the evidence was presented, discussed, and overarching principles and recommendations were updated, followed by voting.RESULTS: Five overarching principles and 15 recommendations with a focus on personalised medicine were agreed: eight remained unchanged from the previous recommendations; three with minor edits on nomenclature; two with relevant updates (#9, 12); two newly formulated (#10, 11). The first five recommendations focus on treatment target and monitoring, non-pharmacological management and non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice pharmacological treatment. Recommendations 6-8 deal with analgesics and discourage long-term glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for pure axial involvement. Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i)) and targeted synthetic DMARDs (tsDMARDs, ie, Janus kinase inhibitors) for patients who have Ankylosing Spondylitis Disease Activity Score ≥2.1 and failed ≥2 NSAIDs and also have either elevated C reactive protein, MRI inflammation of sacroiliac joints or radiographic sacroiliitis. Current practice is to start a TNFi or IL-17i. Recommendation 10 addresses extramusculoskeletal manifestations with TNF monoclonal antibodies preferred for recurrent uveitis or inflammatory bowel disease, and IL-17i for significant psoriasis. Treatment failure should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities (#11). If active axSpA is confirmed, swi

Published
2023

11. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Author

Webers, Casper, Ortolan, Augusta, Sepriano, Alexandre, Falzon, Louise, Baraliakos, Xenofon, Landewé, Robert B M, Ramiro, Sofia, van der Heijde, Désirée, Nikiphorou, Elena, Webers, Casper, Ortolan, Augusta, Sepriano, Alexandre, Falzon, Louise, Baraliakos, Xenofon, Landewé, Robert B M, Ramiro, Sofia, van der Heijde, Désirée, and Nikiphorou, Elena

Abstract

OBJECTIVE: To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA.METHODS: Systematic literature review (2016-2021) on efficacy and safety of bDMARDs in axSpA (radiographic axSpA (r-axSpA)/non-radiographic axSpA (nr-axSpA)). Eligible study designs included randomised controlled trials (RCTs), strategy trials and observational studies (the latter only for safety and extra-musculoskeletal manifestations). All relevant efficacy/safety outcomes were included.RESULTS: In total, 148 publications were included. Efficacy of golimumab and certolizumab was confirmed. Tumour necrosis factor inhibitor (TNFi) biosimilar-originator equivalence was demonstrated. RCT (n=15) data on efficacy of interleukin-17 inhibitors (IL-17i) demonstrated clinically relevant effects (risk ratio vs placebo to achieve ASAS40 response 1.3-15.3 (r-axSpA, n=9), 1.4-2.1 (nr-axSpA, n=2)). Efficacy of secukinumab/ixekizumab was demonstrated in TNFi-naïve and TNFi-inadequate responders. IL-23 and IL-12/23 inhibitors (risankizumab/ustekinumab) failed to show relevant benefits. Tapering of TNFi by spacing was non-inferior to standard-dose treatment. The first axSpA treat-to-target trial did not meet its primary endpoint, but showed improvements in secondary outcomes. No new risks were identified with TNFi use in observational studies (data lacking for IL-17i). Secukinumab (n=1) and etanercept (n=2) were associated with increased risk of uveitis in observational studies compared to monoclonal TNFi.CONCLUSIONS: New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA, while IL-23i failed to show relevant effects. Observational studies ar

Published
2023

12. Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.

Author

van der Heijde, Désirée, Molto, Anna, Ramiro, Sofia, Braun, Jürgen, Dougados, Maxime, van Gaalen, Floris A., Gensler, Lianne S., Inman, Robert D., Landewé, Robert B. M., Marzo-Ortega, Helena, Navarro-Compán, Victoria, Phoka, Andri, Poddubnyy, Denis, Protopopov, Mikhail, Reveille, John, Rudwaleit, Martin, Sampaio-Barros, Percival, Sepriano, Alexandre, Sieper, Joachim, and den Bosch, Filip E. Van

Published
2024
Full Text
View/download PDF

13. Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

Author

Ghiti Moghadam, Marjan, Lamers-Karnebeek, Femke B. G., Vonkeman, Harald E., ten Klooster, Peter M., Tekstra, Janneke, van Schaeybroeck, Barbara, Klaasen, Ruth, van Onna, Marieke, Bernelot Moens, Hein J., Visser, Henk, Schilder, Annemarie M., Kok, Marc R., Landewé, Robert B. M., van Riel, Piet L. C. M., van de Laar, Mart A. F. J., Jansen, Tim L., and on behalf of the Dutch National POET Collaboration

Published
2019
Full Text
View/download PDF

14. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.

Author

Ritchlin, Christopher T., Coates, Laura C., McInnes, Iain B., Mease, Philip J., Merola, Joseph F., Yoshiya Tanaka, Akihiko Asahina, Gossec, Laure, Gottlieb, Alice B., Warren, Richard B., Ink, Barbara, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, and Landewé, Robert B. M.

Published
2023
Full Text
View/download PDF

15. Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more

Author

Boone, Niels W., primary, Moes, Dirk Jan A. R., additional, Ramiro, Sofia, additional, Mostard, Remy L. M., additional, Magro‐Checa, Cesar, additional, van Dongen, Christel M. P., additional, Gronenschild, Michiel, additional, van Haren, Eric, additional, Buijs, Jacqueline, additional, de Vries, Annick, additional, Peeters, Ralph, additional, Landewé, Robert B. M., additional, and Wong, Dennis R., additional

Published
2023
Full Text
View/download PDF

16. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Author

Smolen, Josef S., Landewé, Robert B. M., Bergstra, Sytske Anne, Kerschbaumer, Andreas, Sepriano, Alexandre, Aletaha, Daniel, Caporali, Roberto, Edwards, Christopher John, Hyrich, Kimme L., Pope, Janet E., de Souza, Savia, Stamm, Tanja A., Takeuchi, Tsutomu, Verschueren, Patrick, Winthrop, Kevin L., Balsa, Alejandro, Bathon, Joan M., Buch, Maya H., Burmester, Gerd R., Buttgereit, Frank, Cardiel, Mario Humberto, Chatzidionysiou, Katerina, Codreanu, Catalin, Cutolo, Maurizio, den Broeder, Alfons A., el Aoufy, Khadija, Finckh, Axel, Fonseca, João Eurico, Gottenberg, Jacques-Eric, Haavardsholm, Espen A., Iagnocco, Annamaria, Lauper, Kim, Li, Zhanguo, McInnes, Iain B., Mysler, Eduardo F., Nash, Peter, Poor, Gyula, Ristic, Gorica G., Rivellese, Felice, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Stoilov, Nikolay, Strangfeld, Anja, van der Helm-van Mil, Annette, van Duuren, Elsa, Vliet Vlieland, Theodora P. M., Westhovens, René, van der Heijde, D. sirée, Clinical Immunology and Rheumatology, and AII - Inflammatory diseases

Subjects
Arthritis, Rheumatoid, Biological Therapy, All institutes and research themes of the Radboud University Medical Center, Rheumatology, Arthritis, Rheumatoid, Antirheumatic Agents, Immunology, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology
Abstract

ObjectivesTo provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.MethodsAn international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item.ResultsThe task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3–6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations.ConclusionsThese updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.

Published
2023
Full Text
View/download PDF

17. Progression From Subclinical Inflammation to Overt Spondyloarthritis (SpA) in First-Degree Relatives of SpA Patients in Association With HLA-B27: the Pre-SpA cohort

Author

de Jong, Henriëtte M Y, de Winter, Janneke J H, van der Horst-Bruinsma, Irene E, van Schaardenburg, Dirk-Jan, van Gaalen, Floris A, van Tubergen, Astrid M, Weel, Angelique E A M, Landewé, Robert B M, Baeten, Dominique L P, van de Sande, Marleen G H, Interne Geneeskunde, MUMC+: MA Reumatologie (9), and RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation

Subjects
musculoskeletal diseases
Abstract

OBJECTIVES: As first-degree relatives (FDRs) of HLA-B27-positive axial spondyloarthritis (axSpA) patients have an increased risk of developing axSpA, the objectives were 1) to evaluate presence of highly specific imaging features as well as clinical signs of SpA at baseline and after one year of follow-up, and 2) describe the evolution towards clinical disease within one year of follow-up in a cohort of seemingly healthy FDRs of HLA-B27 positive axSpA patients. METHODS: The Pre-SpA cohort is a 5-year prospective inception cohort of seemingly healthy FDRs of HLA-B27 positive axSpA patients. Clinical and imaging features were collected and recorded. RESULTS: At baseline 19% of the FDRs reported inflammatory back pain. Thirty-two percent reported current arthralgia, 3% arthritis (ever), 5% enthesitis (ever) and 1% dactylitis (ever). Three percent had an extra-articular manifestation. CRP was elevated in 16%, ESR in 7%. On MRI-SIJ, 10% had a SPARCC score ≥2, 4% ≥5, and 4% deep lesions. One percent fulfilled the mNY criteria for radiographic sacroiliitis. Clinical, MRI and acute phase findings were equally distributed between HLA-B27 positive and negative FDRs. After 1 year of follow-up, clinical parameters did not change on the group level but 6% of the FDRs were clinically diagnosed with axSpA, of whom 86% were HLA-B27 positive. CONCLUSION: Features associated with spondyloarthritis or imaging abnormalities were found in up to 32% of seemingly healthy FDRs, with an equal distribution between HLA-B27 positive and negative FDRs. Progression to clinical axSpA within 1 year of follow-up was mainly observed in HLA-B27 positive FDRs.

Published
2022

18. The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study

Author

Wientjes, Maike H M, primary, Ulijn, Evy, additional, Kievit, Wietske, additional, Landewé, Robert B M, additional, Meek, Inger, additional, den Broeder, Nathan, additional, van Herwaarden, Noortje, additional, van den Bemt, Bart J F, additional, Verhoef, Lise M, additional, and den Broeder, Alfons A, additional

Published
2022
Full Text
View/download PDF

20. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Bergstra, Sytske Anne, primary, Sepriano, Alexandre, additional, Kerschbaumer, Andreas, additional, van der Heijde, Désirée, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Verschueren, Patrick, additional, de Souza, Savia, additional, Pope, Janet E, additional, Takeuchi, Tsutomu, additional, Hyrich, Kimme L, additional, Winthrop, Kevin L, additional, Aletaha, Daniel, additional, Stamm, Tanja A, additional, Schoones, Jan W, additional, Smolen, Josef S, additional, and Landewé, Robert B M, additional

Published
2022
Full Text
View/download PDF

21. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Sepriano, Alexandre, primary, Kerschbaumer, Andreas, additional, Bergstra, Sytske Anne, additional, Smolen, Josef S, additional, van der Heijde, Désirée, additional, Caporali, Roberto, additional, Edwards, Christopher J, additional, Verschueren, Patrick, additional, de Souza, Savia, additional, Pope, Janet, additional, Takeuchi, Tsutomu, additional, Hyrich, Kimme, additional, Winthrop, Kevin L, additional, Aletaha, Daniel, additional, Stamm, Tanja, additional, Schoones, Jan W, additional, and Landewé, Robert B M, additional

Published
2022
Full Text
View/download PDF

22. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Kerschbaumer, Andreas, primary, Sepriano, Alexandre, additional, Bergstra, Sytske Anne, additional, Smolen, Josef S, additional, van der Heijde, Désirée, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Verschueren, Patrick, additional, de Souza, Savia, additional, Pope, Janet E, additional, Takeuchi, Tsutomu, additional, Hyrich, Kimme L, additional, Winthrop, Kevin L, additional, Aletaha, Daniel, additional, Stamm, Tanja A, additional, Schoones, Jan W, additional, and Landewé, Robert B M, additional

Published
2022
Full Text
View/download PDF

23. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Author

Smolen, Josef S, primary, Landewé, Robert B M, additional, Bergstra, Sytske Anne, additional, Kerschbaumer, Andreas, additional, Sepriano, Alexandre, additional, Aletaha, Daniel, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Hyrich, Kimme L, additional, Pope, Janet E, additional, de Souza, Savia, additional, Stamm, Tanja A, additional, Takeuchi, Tsutomu, additional, Verschueren, Patrick, additional, Winthrop, Kevin L, additional, Balsa, Alejandro, additional, Bathon, Joan M, additional, Buch, Maya H, additional, Burmester, Gerd R, additional, Buttgereit, Frank, additional, Cardiel, Mario Humberto, additional, Chatzidionysiou, Katerina, additional, Codreanu, Catalin, additional, Cutolo, Maurizio, additional, den Broeder, Alfons A, additional, El Aoufy, Khadija, additional, Finckh, Axel, additional, Fonseca, João Eurico, additional, Gottenberg, Jacques-Eric, additional, Haavardsholm, Espen A, additional, Iagnocco, Annamaria, additional, Lauper, Kim, additional, Li, Zhanguo, additional, McInnes, Iain B, additional, Mysler, Eduardo F, additional, Nash, Peter, additional, Poor, Gyula, additional, Ristic, Gorica G, additional, Rivellese, Felice, additional, Rubbert-Roth, Andrea, additional, Schulze-Koops, Hendrik, additional, Stoilov, Nikolay, additional, Strangfeld, Anja, additional, van der Helm-van Mil, Annette, additional, van Duuren, Elsa, additional, Vliet Vlieland, Theodora P M, additional, Westhovens, René, additional, and van der Heijde, Désirée, additional

Published
2022
Full Text
View/download PDF

24. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Author

Webers, Casper, primary, Ortolan, Augusta, additional, Sepriano, Alexandre, additional, Falzon, Louise, additional, Baraliakos, Xenofon, additional, Landewé, Robert B M, additional, Ramiro, Sofia, additional, van der Heijde, Désirée, additional, and Nikiphorou, Elena, additional

Published
2022
Full Text
View/download PDF

25. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Author

Ramiro, Sofia, primary, Nikiphorou, Elena, additional, Sepriano, Alexandre, additional, Ortolan, Augusta, additional, Webers, Casper, additional, Baraliakos, Xenofon, additional, Landewé, Robert B M, additional, Van den Bosch, Filip E, additional, Boteva, Boryana, additional, Bremander, Ann, additional, Carron, Philippe, additional, Ciurea, Adrian, additional, van Gaalen, Floris A, additional, Géher, Pál, additional, Gensler, Lianne, additional, Hermann, Josef, additional, de Hooge, Manouk, additional, Husakova, Marketa, additional, Kiltz, Uta, additional, López-Medina, Clementina, additional, Machado, Pedro M, additional, Marzo-Ortega, Helena, additional, Molto, Anna, additional, Navarro-Compán, Victoria, additional, Nissen, Michael J, additional, Pimentel-Santos, Fernando M, additional, Poddubnyy, Denis, additional, Proft, Fabian, additional, Rudwaleit, Martin, additional, Telkman, Mark, additional, Zhao, Sizheng Steven, additional, Ziade, Nelly, additional, and van der Heijde, Désirée, additional

Published
2022
Full Text
View/download PDF

26. Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Author

Combe, Bernard G., primary, Tanaka, Yoshiya, additional, Buch, Maya H., additional, Nash, Peter, additional, Burmester, Gerd R., additional, Kivitz, Alan J., additional, Bartok, Beatrix, additional, Pechonkina, Alena, additional, Xia, Katrina, additional, Emoto, Kahaku, additional, Kano, Shungo, additional, Hendrikx, Thijs K., additional, Landewé, Robert B. M., additional, and Aletaha, Daniel, additional

Published
2022
Full Text
View/download PDF

27. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis

Author

Dougados, Maxime, Maksymowych, Walter P, Landewé, Robert B M, Moltó, Anna, Claudepierre, Pascal, de Hooge, Manouk, Lambert, Robert G, Bonin, Randi, Bukowski, Jack F, Jones, Heather E, Logeart, Isabelle, Pedersen, Ron, Szumski, Annette, Vlahos, Bonnie, and van der Heijde, Désirée

Published
2018
Full Text
View/download PDF

28. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS

Author

Molto, Anna, Gossec, Laure, Meghnathi, Bhowmik, Landewé, Robert B M, van der Heijde, Désirée, Atagunduz, Pamir, Elzorkany, Bassel Kamal, Akkoc, Nurullah, Kiltz, Uta, Gu, Jieruo, Wei, James Cheng Chung, Dougados, Maxime, Molto, A, Gossec, L, Meghnathi, B, RLANDEWE, Der heijde, D Van, Atagunduz, P, Zorkany, B El, Akkoc, N, Kiltz, U, Gu, J, Wei, J Cheng-chung, Pandya, M Dougados,s, Navarro, V, Gaydukova, I, Geher, P, Spoorenberg, A, Aydin, S, Pimentel, F, Kishimoto, M, Gallen, F Van, Collantes-estevez, E, Schiotis, R, Marzo-ortega, H, O’shea, B, Ramos-remus, C, and Magrey, And M

Published
2018
Full Text
View/download PDF

30. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort

Author

Molnar, Christoph, Scherer, Almut, Baraliakos, Xenofon, de Hooge, Manouk, Micheroli, Raphael, Exer, Pascale, Kissling, Rudolf O, Tamborrini, Giorgio, Wildi, Lukas M, Nissen, Michael J, Zufferey, Pascal, Bernhard, Jürg, Weber, Ulrich, Landewé, Robert B M, van der Heijde, Désirée, and Ciurea, Adrian

Published
2018
Full Text
View/download PDF

31. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: Efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Author

Landewé, Robert B. M., Gensler, Lianne S., Poddubnyy, Denis, Rahman, Proton, Hojnik, Maja, Li, Xiaoqi, Liu Leage, Soyi, Adams, David, Carlier, Hilde, Van den Bosch, Filip, COAST-Y study group, the, Clinical Immunology and Rheumatology, and AII - Inflammatory diseases

Subjects
medicine.medical_specialty, antirheumatic agents, Immunology, immune system diseases, Genetics and Molecular Biology, Placebo, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Rheumatology, Internal medicine, Spondyloarthritis, Medicine and Health Sciences, Medicine, Humans, Immunology and Allergy, CRITERIA, In patient, Spondylitis, Ankylosing, 030212 general & internal medicine, Axial spondyloarthritis, Spondylitis, 030203 arthritis & rheumatology, DISEASE-ACTIVITY STATES, Ankylosing spondylitis, business.industry, Extension study, ANKYLOSING-SPONDYLITIS, spondylitis, medicine.disease, SHORT-TERM IMPROVEMENT, Ixekizumab, Treatment Outcome, DEFINITION, ankylosing, biological therapy, General Biochemistry, business, Axial Spondyloarthritis
Abstract

ObjectivesThe objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission.MethodsCOAST-Y is an ongoing, phase III, long-term extension study that included a double-blind, placebo (PBO)-controlled, randomised withdrawal-retreatment period (RWRP). Patients who completed the originating 52-week COAST-V, COAST-W or COAST-X studies entered a 24-week lead-in period and continued either 80 mg IXE every 2 (Q2W) or 4 weeks (Q4W). Patients who achieved remission (an Ankylosing Spondylitis Disease Activity Score (ASDAS)3.5 at any visit) after the 40-week RWRP, with time-to-flare as a major secondary endpoint.ResultsOf 773 enrolled patients, 741 completed the 24-week lead-in period and 155 entered the RWRP. Forty weeks after randomised withdrawal, 83.3% of patients in the combined IXE (85/102, pConclusionsPatients with axSpA who continued treatment with IXE were significantly less likely to flare and had significantly delayed time-to-flare compared with patients who withdrew to PBO.

Published
2021
Full Text
View/download PDF

33. Controversies in rheumatology: telemedicine—friend or foe?

Author

Dejaco, Christian and Landewé, Robert B M

Subjects
*MEDICAL quality control, *MEDICAL consultation, *HEALTH policy, *MEDICAL triage, *PATHOGENESIS, *RHEUMATOLOGY, *DEBATE, *PHYSICAL therapy, *MEDICAL care use, *HEALTH, *INFORMATION resources, *INFORMATION retrieval, *QUALITY of life, *INFORMATION science, *PATIENT education, *PATIENT-professional relations, *COVID-19 pandemic, *TELEMEDICINE, *PSYCHOTHERAPY
Abstract

Telemedicine is increasingly used in rheumatology. While telemedicine guaranteed care of patients during the COVID-19 pandemic, it is now increasingly used to facilitate triage of patients, monitoring of disease activity, and patients' education. In addition, tele-visits as well as remote physio- and psychotherapy are replacing traditional face-to-face contacts between patients and their healthcare provider. While this may save resources in a world in which the gap between the demand and the provision of healthcare increases, there is also a danger of losing essential information, for example by non-verbal communication, that can only be retrieved during face-to-face contact in the office. In addition, it may be challenging to build a trusting relationship between patients and healthcare professionals by virtual means only. Globally acting companies that see market opportunities already amply offer 'simple' technical solutions for telemedicine. While such solutions may seem (economically) interesting at first glance, there is a risk of monopolization, leaving the most valuable parts of healthcare to a small number of profit-seeking companies. In this article, the opportunities and threats of telemedicine in rheumatology are debated. A possible way forward is to complement traditional face-to-face visits with information gained by telemedicine, in order to render these consultations more efficient rather than replacing personal contact by technology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study.

Author

Wientjes, Maike H M, Ulijn, Evy, Kievit, Wietske, Landewé, Robert B M, Meek, Inger, Broeder, Nathan den, Herwaarden, Noortje van, Bemt, Bart J F van den, Verhoef, Lise M, and Broeder, Alfons A den

Subjects
BIOMARKERS, STRATEGIC planning, MATHEMATICAL models, COST control, MEDICAL care costs, TREATMENT effectiveness, COMPARATIVE studies, RHEUMATOID arthritis, THEORY, COST effectiveness, PREDICTIVE validity, SENSITIVITY & specificity (Statistics), PROBABILITY theory, DISEASE remission, EVALUATION
Abstract

Objectives To quantify the additional value of a hypothetical biomarker predicting response to treatment for RA regarding efficacy and costs by using a modelling design. Methods A Markov model was built comparing a usual care T2T strategy with a biomarker-steered strategy for RA patients starting biologic therapy. Outcome measures include time spent in remission or low disease activity (LDA) and costs. Four additional scenario analyses were performed by varying biomarker or clinical care characteristics: (i) costs of the biomarker; (ii) sensitivity and specificity of the biomarker; (iii) proportion of eligible patients tapering; and (iv) medication costs. Results In the base model, patients spent 2.9 months extra in LDA or remission in the biomarker strategy compared with usual care T2T over 48 months. Total costs were €43 301 and €42 568 for, respectively, the usual care and biomarker strategy, and treatment costs accounted for 91% of total costs in both scenarios. Cost savings were driven due to patients in the biomarker strategy experiencing remission or LDA earlier, and starting tapering sooner. Cost-effectiveness was not so much driven by costs or test characteristics of the biomarker (scenario 1/2), but rather by the level of early and proactive tapering and drug costs (scenarios 3/4). Conclusions The use of a biomarker for prediction of response to b/tsDMARD treatment in RA can be of added value to current treat-to-target clinical care. However, gains in efficacy are modest and cost gains are depending on a combination of early proactive tapering and high medication costs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

Author

Landewé, Robert B M, primary, Poddubnyy, Denis, additional, Rahman, Proton, additional, Van den Bosch, Filip E, additional, Bolce, Rebecca, additional, Liu Leage, Soyi, additional, Lisse, Jeffrey R, additional, Park, So Young, additional, and Gensler, Lianne, additional

Published
2022
Full Text
View/download PDF

40. Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort

Author

de Jong, Henriëtte M. Y., primary, de Winter, Janneke J. H., additional, van der Horst‐Bruinsma, Irene E., additional, van Schaardenburg, Dirk‐Jan, additional, van Gaalen, Floris A., additional, van Tubergen, Astrid M., additional, Weel, Angelique E. A. M., additional, Landewé, Robert B. M., additional, Baeten, Dominique L. P., additional, and van de Sande, Marleen G. H., additional

Published
2022
Full Text
View/download PDF

42. MRI lesions of the spine in patients with axial spondyloarthritis:an update of lesion definitions and validation by the ASAS MRI working group

Author

Baraliakos, Xenofon, Østergaard, Mikkel, Lambert, Robert G. W., Eshed, Iris, Machado, Pedro M., Pedersen, Susanne Juhl, Weber, Ulrich, de Hooge, Manouk, Sieper, Joachim, Poddubnyy, Denis, Rudwaleit, Martin, Van Der Heijde, Désirée, Landewé, Robert B. M., Maksymowych, Walter P., Baraliakos, Xenofon, Østergaard, Mikkel, Lambert, Robert G. W., Eshed, Iris, Machado, Pedro M., Pedersen, Susanne Juhl, Weber, Ulrich, de Hooge, Manouk, Sieper, Joachim, Poddubnyy, Denis, Rudwaleit, Martin, Van Der Heijde, Désirée, Landewé, Robert B. M., and Maksymowych, Walter P.

Abstract

Objectives: Spinal MRI is used to visualise lesions associated with axial spondyloarthritis (axSpA). The ASAS MRI working group (WG) updated and validated the definitions for inflammatory and structural spinal lesions in the context of axSpA. Methods: After review of the existing literature on all possible types of spinal MRI pathologies in axSpA, the group (12 rheumatologists and two radiologists) consented on the required revisions of lesion definitions compared with the existing nomenclature of 2012. In a second step, using 62 MRI scans from the ASAS classification cohort, the proposed definitions were validated in a multireader campaign by global (absent/present) and detailed (inflammation and structural) lesion assessment at the vertebral corner (VC), vertebral endplate, facet joints, transverse processes, lateral and posterior elements. Intraclass correlation coefficient (ICC) was used for analysis. Results: Revisions were made for both inflammatory (bone marrow oedema, BMO) and structural (fat, erosion, bone spur and ankylosis) lesions, including localisation (central vs lateral), extension (VC vs vertebral endplate) and extent (minimum number of slices needed), while new definitions were suggested for the type of lesion based on lesion maturity (VC monomorphic vs dimorphic). The most reliably assessed lesions were VC fat lesion and VC monomorphic BMO (ICC (mean of all 36 reader pairs/overall 9 readers): 0.91/0.92; 0.70/0.67, respectively. Conclusions: The lesion definitions for spinal MRI lesions compatible with SpA were updated by consensus and validated by a group of experienced readers. The lesions with the highest frequency and best reliability were fat and monomorphic inflammatory lesions at the VC.

Published
2022

47. Instrument selection for the ASAS core outcome set for axial spondyloarthritis.

Author

Navarro-Compán, Victoria, Boel, Anne, Boonen, Annelies, Mease, Philip J., Dougados, Maxime, Kiltz, Uta, Landewé, Robert B. M., Baraliakos, Xenofon, Bautista-Molano, Wilson, Chiowchanwisawakit, Praveena, Dagfinrud, Hanne, Fallon, Lara, Garrido-Cumbrera, Marco, Gensler, Lianne, ElZorkany, Bassel Kamal, Haroon, Nigil, Yu Heng Kwan, Machado, Pedro M., Maksymowych, Walter, and Molto, Anna

Published
2023
Full Text
View/download PDF

50. Instrument selection for the ASAS core outcome set for axial spondyloarthritis

Author

Navarro-Compán, Victoria, primary, Boel, Anne, additional, Boonen, Annelies, additional, Mease, Philip J, additional, Dougados, Maxime, additional, Kiltz, Uta, additional, Landewé, Robert B M, additional, Baraliakos, Xenofon, additional, Bautista-Molano, Wilson, additional, Chiowchanwisawakit, Praveena, additional, Dagfinrud, Hanne, additional, Fallon, Lara, additional, Garrido-Cumbrera, Marco, additional, Gensler, Lianne, additional, ElZorkany, Bassel Kamal, additional, Haroon, Nigil, additional, Kwan, Yu Heng, additional, Machado, Pedro M, additional, Maksymowych, Walter, additional, Molto, Anna, additional, de Peyrecave, Natasha, additional, Poddubnyy, Denis, additional, Protopopov, Mikhail, additional, Ramiro, Sofia, additional, Song, In-Ho, additional, van Weely, Salima, additional, and van der Heijde, Désirée, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results